Published in Gene Therapy Weekly, April 4th, 2002
Researchers affiliated with the Massachusetts General Hospital and Harvard Medical School in Boston, Massachusetts, have examined whether antisense gene therapy could reverse negative factors influencing human heart failure by studying the myocardial cells of nine patients with end-stage heart failure. They believe that controlling an important protein, phospholamban, may hold the key.
"We tested whether contractile function can be improved by decreasing the inhibitory effects of phospholamban on...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.